EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

FDG and FAPI PET–based response evaluation to reduced‐dose nivolumab in pleural mesothelioma: A case report

Morten Bentestuen, Anne H Thostrup, Weronika M Szejniuk, Zsuzsanna Takacs-Szabo, Thor L Rasmussen, Helle D Zacho iD

Clinical Physiology and Functional Imaging · 2026

DOI: 10.1111/cpf.70053 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Physiology and Functional Imaging, 2026. Verfasst von Morten Bentestuen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Pleural Neoplasms, Radiopharmaceuticals. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reliable tools for objective response assessment are essential in pleural mesothelioma treated with immunotherapy. We report on a 75‐year‐old man with sarcomatoid pleural mesothelioma who received a reduced nivolumab dose after developing a hypersensitivity reaction during the first infusion. CT, [ 18 F]FDG PET/CT and [ 68 Ga]Ga‐Fibroblast activation protein inhibitor‐46 (FAPI) PET/CT were performed before and after treatment. Despite the reduced dose, the patient experienced clear clinical benefit, and follow‐up imaging demonstrated substantial morphological and metabolic improvement across all imaging modalities. This case offers an unique opportunity to directly compare response assessment across three complimentary imaging modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyPleural NeoplasmsRadiopharmaceuticalsMesotheliomaNivolumabAntineoplastic Agents, ImmunologicalLung NeoplasmsHumansMaleAgedTreatment OutcomePredictive Value of TestsFibroblast Activation Protein AlphaMesothelioma, MalignantGallium Radioisotopes

Stichwörter der Autor:innen

CTFAPIFDGPETpleural mesotheliomaresponse assessment

Substanzen

Fluorodeoxyglucose F18RadiopharmaceuticalsFibroblast Activation Protein AlphaNivolumabAntineoplastic Agents, ImmunologicalGallium Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Oncology and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Radiology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Respiratory Disease, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Helle D Zacho

Zitieren

APA

Bentestuen, M., Thostrup, A. H., Szejniuk, W. M., Takacs-Szabo, Z., Rasmussen, T. L., & Zacho, H. D. (2026). FDG and FAPI PET–based response evaluation to reduced‐dose nivolumab in pleural mesothelioma: A case report. Clinical Physiology and Functional Imaging. https://doi.org/10.1111/cpf.70053

Vancouver

Bentestuen M, Thostrup AH, Szejniuk WM, Takacs-Szabo Z, Rasmussen TL, Zacho HD. FDG and FAPI PET–based response evaluation to reduced‐dose nivolumab in pleural mesothelioma: A case report. Clinical Physiology and Functional Imaging. 2026. doi:10.1111/cpf.70053

BibTeX
@article{Bentestuen2026,
  author = {Bentestuen, Morten and Thostrup, Anne H and Szejniuk, Weronika M and Takacs-Szabo, Zsuzsanna and Rasmussen, Thor L and Zacho, Helle D},
  title = {FDG and FAPI PET–based response evaluation to reduced‐dose nivolumab in pleural mesothelioma: A case report},
  journal = {Clinical Physiology and Functional Imaging},
  year = {2026},
  doi = {10.1111/cpf.70053}
}
Kostenlos starten →